Improving Delivery Of Secondary Prophylaxis For Rheumatic Heart Disease: A Stepped-wedge, Community-randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,913,074.00
Summary
Rheumatic heart disease (RHD) is a major health problem in Indigenous communities. Continued progress in controlling RHD requires an understanding of how to improve delivery of regular injections of penicillin - secondary prophylaxis (SP). We will evaluate a systems-based approach to improving delivery of SP, using a stepped-wedge trial in 12 communities in NT and Qld. If successful, this model will provide a practical and transferable model.
A Population-based Record Linkage Study Of The Impact Of Chlamydia Infection On Reproductive Health In Women
Funder
National Health and Medical Research Council
Funding Amount
$405,114.00
Summary
Chlamydia is the most commonly notified infection in young Australian women and reports of cases are increasing. While chlamydia is thought to result in infertility and ectopic pregnancy in later life, the evidence for this is limited. This will be the largest, most comprehensive study in the world to determine the risk of infertility and ectopic pregnancy following chlamydia infection. The results will provide vital information to more cost-effectively plan strategies to control chlamydia in Au ....Chlamydia is the most commonly notified infection in young Australian women and reports of cases are increasing. While chlamydia is thought to result in infertility and ectopic pregnancy in later life, the evidence for this is limited. This will be the largest, most comprehensive study in the world to determine the risk of infertility and ectopic pregnancy following chlamydia infection. The results will provide vital information to more cost-effectively plan strategies to control chlamydia in Australia.Read moreRead less
SCALE-C: Strategies For Hepatitis C Testing And Treatment In Aboriginal Communities That Lead To Elimination
Funder
National Health and Medical Research Council
Funding Amount
$2,175,170.00
Summary
Prevalence of hepatitis C infection within the Aboriginal population is among the highest of any identifiable population in Australia. Highly effective, direct-acting antiviral (DAA) therapy, and their listing on the PBS in 2016 has revolutionised HCV clinical management in Australia. The SCALE-C study will evaluate an established test and treat model to rapidly scale-up DAA within four Aboriginal communities to determine both impact on community prevalence and ongoing transmission.